Protalex Inc

Protalex — Technical Presentation (November 2012)

28 slides from Protalex's technical presentation, Nov 13, 2012

  1. Slide 1: Phase 1 Study of Intravenous Staphylococcal Protein A in Rheumatoid Arthritis

    Edward Bernton MD, 1 Eduard Krantz MD, 2 William Gannon MD 1 1 Protalex Inc., Summit, NJ, USA 2 Parexel Clinical Pharmacology, Bloemfontein, South Africa A Phase 1, Randomized, Double - blind, Placebo - controlled Multiple - dose Study of Intravenous Staphylococcal Protein A in Patients with Active

  2. Slide 2: Forward Looking Statements Information

    FORWARD LOOKING STATEMENTS INFORMATION  Various statements made in this presentation are forward - looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward - looking statements include those which express plan, anticipation, intent, contingency, goals, target

  3. Slide 3: Disclosures

    Disclosures  Study funded by Protalex Inc., Summit, NJ  Drs Bernton and Gannon serve as paid consultants to Protalex Inc.  Dr Krantz, country Principal Investigator for the study, is an employee of Parexel Clinical Pharmacology, contracted by Protalex Inc. to conduct the study

  4. Slide 4: Highly purified Staphylococcal Protein A (SpA)

    PRTX - 100  Highly purified Staphylococcal Protein A (SpA)  42 kDa bacterial membrane protein composed of five homologous 58 – 61 amino acid immunoglobulin binding domains – Binds to Fc region of IgG – Binds with high affinity to Fab framework region of Clade Vh3 Igs (most auto - antibodies [autoA

  5. Slide 5: SpA immuno-adsorption column and prior Protalex Phase I studies

    PRTX - 100  SpA immuno - adsorption column approved in 1999 as medical device for treatment of refractory RA – Responses after 6 – 12 weekly treatments – Often maintained for ≥10 months  MOA not adsorption of autoAbs but exposure to leached SpA – 400 – 1200 μ g per Rx in returned plasma ≈5 – 15 μ

  6. Slide 6: Phase Ib RCT in RA: Objectives

    PRTX - 100 - 103 Phase Ib RCT in RA: Objectives Primary  Assess safety and tolerability of IV SpA weekly x 4 doses Secondary  Assess immunogenicity after ≥3 doses  Determine PK and estimate of PRTX - 100 plasma exposure after first and fourth dose  Determine whether a relationship exists between

  7. Slide 7: Study Design

    PRTX - 100 - 103: Study Design  Sequential cohorts (ratio 8 active:2 placebo) randomized to receive 0.15, 0.45, 0.9 or 1.5 µg/kg IV Week 0 1 2 3 6 4 10 8 12 16 Dosing ACR & DAS assessments Anti - SPA ABS 90 days PK profile CBC, CHEM,U/A

  8. Slide 8: Patient Eligibility

    Patient Eligibility  Key inclusion criteria: – Age ≥18 years with diagnosis of RA for ≥6 months – Active RA: ≥8 SJC; ≥10 TJC (58/60 count); hs - CRP ≥0.5 mg/dL – MTX (7.5 – 25 mg/week) for ≥3 months; stable doses ≥4 weeks – NSAIDS or low - dose prednisone (≤10 mg/day); doses stable ≥2 weeks – HCQ/C

  9. Slide 9: Disease Activity Endpoints

    Disease Activity Endpoints Primary outcome measure  Number (%) of patients attaining DAS28 - CRP <3.2 = low disease activity by Week 6 Other outcome measures  Absolute and percentage change from baseline of DAS28 - CRP across study timepoints (through 16 weeks)  Change from baseline in Clinical D

  10. Slide 10: Patient Disposition

    Patient Disposition PRTX - 100 (μg/kg) No. of patients (%) 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5) Placebo (n=8) Completed week 16 7 (87.5) 6 (75) 7 (87.5) 5 (100) 7 (87.5) Discontinued prematurely 1 (12.5) 2 (25) 1 (12.5) 0 1 (12.5) Reason for premature discontinuation: Consent withdrawal 0 0 1

  11. Slide 11: Baseline Demographics and Disease Characteristics

    Baseline Demographics and Disease Characteristics PRTX - 100 (μg/kg) Characteristic 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5) Placebo (n=8) Mean age, y 51.0 54.6 46.1 47.0 46.5 Caucasian, % 50 87.5 37.5 60 50 Median disease duration, y 7.7 9.6 6.8 3.8 2.9 Mean TJC (28 joint) 20.6 15.3 13.9 15.0 16.

  12. Slide 12: Safety: Serious Adverse Events

    Safety: Serious Adverse Events  SAEs: – 0.45 μ g/kg – fracture of L humerus – 0.45 μ g/kg – acute gastritis and colitis, resolved after discontinuation of meloxicam and treatment with PPI and 5 - ASA , no acute colonoscopy, no biopsy patient withdrew from study during follow - up phase – 0.9 μ g/kg

  13. Slide 13: Common Related Treatment-Emergent AEs

    Common (≥5%) Related Treatment - Emergent AEs  Several were components of acute infusion reactions: included mild – moderate nausea, dizziness, muscle spasms, and flushing PRTX - 100 (μg/kg) Event, n (%) 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5) Placebo (n=8) Nausea 1 (12.5) 2 (25) 2 (25) 0 0 Musc

  14. Slide 14: Most Common Treatment-Emergent AEs

    Most Common Treatment - Emergent AEs (≥12% in all PRTX - 100 group) PRTX - 100 (μg/kg) Event, n 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5) All (n=29) Placebo (n=8) Headache 6 6 4 0 16 (55%) 2 (25%) RA flare 4 1 1 2 8 (28%) 1 (13%) Nausea 2 3 2 1 8 (28%) 0 Muscle spasms 1 2 3 0 6 (21%) 1 (13%) Nasoph

  15. Slide 15: Laboratory AEs

    Laboratory AEs  Laboratory findings: – No trends seen in changes from baseline observed in any laboratory parameters in any treatment group – Individual clinically significant lab values included anemia, hyponatremia, hypokalemia, and lymphopenia not felt to be related to PRTX - 100

  16. Slide 16: Acute Infusion Reactions

    Acute Infusion Reactions  No patients received pre - medication before treatments  Three patients (1: 0.45 μg/kg; 2: 0.90 μg/kg) experienced mild to moderate infusion reactions to study drug within 5 min of dosing, all after 3 rd dose  Reactions characterized by dizziness and ≥2 of the following:

  17. Slide 17: Disease Activity: DAS28-CRP score <3.2

    Disease Activity: DAS28 - CRP score <3.2 at Week 6 (primary endpoint) and Week 10 % of patients Week 6 3/29 (10%) Week 6 0/8 Week 10 6/29 (21%) Week 10 0/8

  18. Slide 18: Disease Activity: CDAI Score by Visit (1.5 µg/kg group)

    0 10 20 30 40 50 60 Baseline Wk 2 Wk 4 Wk 6 Wk 8 Wk 10 Wk 12 Wk 16 CDAI Score 1072 1074 4004 4008 5001 Disease Activity: CDAI Score by Visit (1.5 μ g/kg group)

  19. Slide 19: Disease Activity: CDAI ≤10 (Low Disease Activity)

    Disease Activity: CDAI ≤10 (Low Disease Activity) PRTX - 100 (μg/kg) CDAI ≤10, n (%) 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5) Placebo (n=8) Week 2 0 0 0 0 1 (12.5%) Week 6 1 (12.5%) 0 2 (25%) 2 (40%) 1 (12.5%) Week 10 1 (12.5%) 0 2(25%) 2 (40%) 2 (25%) Any 2 consecutive visits 1 (12.5%) 1 (12.5%)

  20. Slide 20: Immunogenicity

    Immunogenicity  At baseline, all patients negative for anti - drug antibodies (ADAs)  21 of 24 active - dosed patients had measurable ADA titers on day 21  No IgE Abs vs SpA using a sensitive ELISA (LLD <1 ng/mL) PRTX - 100 (μg/kg) Day 21 ADA titer * , n 0.15 (n=8) 0.45 (n=8) 0.90 (n=8) 1.5 (n=5)

  21. Slide 21: Plasma PK Parameters after First Dose

    Plasma PK Parameters after First Dose of PRTX - 100 0.9 μg/kg 1.50 μg/kg Parameter Geometric mean Min, max Geometric mean Min, max C max (ng/mL) 26.5 16, 52 51.9 42, 66 AUC (ng/mL*h) 158 18, 388 615 67, 3274 CL (mL/h/kg) 4.9 1.9, 41.6 2.1 0.42, 16.8 Vz (mL/kg) 59 39, 93 45 29, 62 t ½ (h) 8.4 1.6, 19

  22. Slide 22: Pharmacokinetics

    Pharmacokinetics  The relationship of PRTX - 100 dose to C max and AUC was linear, but clearance and AUC were extremely variable within dose cohorts

  23. Slide 23: Plasma Concentrations in Patients with or without ADAs

     Patients with ADAs showed increased plasma clearance of PRTX - 100 by the fourth dose First and Fourth Dose Plasma Concentrations in Individual Patients with or without ADAs No ADAs ADA titer = 2400 0 6 12 18 24 30 36 42 48 0 4 3 2 1 Time since dose (h) Concentration (ng/mL) Day 0 Day 21 Concentra

  24. Slide 24: Relationship Between AUC Ratio and Antibody Titer

    Relationship Between the AUC (0 - t) Ratio Day 21/Day 0 and Antibody Titer Day 21 Antibody Titer AUC (0 - t) ratio day 21/day 0) 0.001 10 0.01 1 0.1 0 <400 >400

  25. Slide 25: ADA Titers of Disease Activity Responders

    Day 21 ADA Titers of Disease Activity Responders (CDAI ≤11 on 2 Visits or More)  Development of ADAs did not appear to preclude a disease activity response Patient No. ADA titer PRTX - 100 dose ( μ g/kg) Responder 02 - 012 207 0.15 Yes 01 - 048 7169 0.45 Yes 01 - 031 3619 0.45 Yes 01 - 058 6848 0.9

  26. Slide 26: Summary

    Summary  Highly purified SpA was well - tolerated: – 3 patients with mild to moderate infusion reactions; this did not recur with slowing the infusion rate – SpA elicited ADAs in the majority of patients but incidence or titer of ADAs was not dose - dependent. No IgE ADAs detected. – Patients with

  27. Slide 27: Conclusions

    Conclusions  This pilot study demonstrated acceptable tolerability and toxicity of four weekly IV doses of PRTX - 100 up to 1.5 µg/kg  There is a suggestion that PRTX - 100 has an effect on disease activity, even in patients with ADAs, which would require confirmation in a larger study.  These fi

  28. Slide 28: Investigators

    Investigators  Dr Eduard Krantz: Parexel International, Bloemfontein, South Africa  Dr Dawie Kruger: Parexel International, George, South Africa  Dr Francios Malan, Dr Reinard McPherson: Parexel International, Port Elizabeth, South Africa  Dr Margare du Toit: Synexus Clinical Research Centre, Pr

Protalex — Technical Presentation (November 2012) on 6ix